Compare AbCellera Biologics Inc (ABCL) vs Workday Inc (WDAY) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Workday (WDAY) trades at $143.65, up 6.09% with strong technical momentum above key resistance at $141. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.66 vs. $2.51 expected) and 14.3% y/y subscription revenue growth. Recent AI product launches, including agentic AI tools with 200%+ ACV growth, position the company for continued expansion despite a recent lawsuit over AI bias in HR tools.

Outlook remains positive with 55.5% analyst buy ratings and $157.30 consensus target (9.5% upside). Key risks include the California AI bias lawsuit, competitive pressure in enterprise software, and valuation concerns at 42.99 P/E. Strong cash flow generation ($2.46B operating cash flow) supports growth investments while net cash flow turned negative due to strategic financing activities.